FDA Approves Lipfendra, A Daily Pill To Lower Cholesterol That Outperforms Statins

FDA Approves Lipfendra, A Daily Pill To Lower Cholesterol That Outperforms Statins Clinical trials of enlicitide, under the brand name Lipfendra, have shown that it can bring levels of LDL — the dangerous type of cholesterol — down to 50 or 60 or even lower, which is far below what can be achieved with statins. The American Heart Association's cholesterol guidelines say LDL levels should be below 70 for those with above-average risk of heart attacks or strokes, The New York Times reported. https://kffhealthnews.org/morning-breakout/lifestyle-and-health-071626/